 |
9 Products |  |
120 Diseases | | 9 Products |
|
46 Trials |  |
2133 News |  |
| «12345678910111213...2930» |
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE: A RETROSPECTIVE ANALYSIS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2777;
In combination with PTCy, short courses of tacrolimus or everolimus and mycophenolate mofetil (MMF) were used as GVHD prophylaxis. Treosulfan-fludarabine conditioning regimen combined with PTCy had low transplantation-related mortality and acceptable relapse rate, especially taking into account the relatively high age of the patients, high or very high DRI in more than half of the patients, and the high proportion of patients with active disease and/or positive MRD at transplant.
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN-BASED HAPLOIDENTICAL T CELL DEPLETED HSCT FOR ADOLESCENTS AND YOUNG ADULTS (AYA) WITH ADVANCED STAGE SICKLE CELL DISEASE AND THALASSEMIA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2776;
The safety and efficacy data of this high-risk AYA patient population with advanced stage hemoglobinopathies reveal that outcome with a T-haplo-HSCT can even exceed that of a MSD-HSCT with regard to a disease-free, GvHD free overall survival (EFS). However, diligent infectious and viral monitoring and early, effective treatment of viral reactivation, in particular HHV6 and CMV is mandatory in SCD pts.
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN-BASED HAPLOIDENTICAL T CELL DEPLETED HSCT FOR ADOLESCENTS AND YOUNG ADULTS (AYA) WITH ADVANCED STAGE SICKLE CELL DISEASE AND THALASSEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2775;
The safety and efficacy data of this high-risk AYA patient population with advanced stage hemoglobinopathies reveal that outcome with a T-haplo-HSCT can even exceed that of a MSD-HSCT with regard to a disease-free, GvHD free overall survival (EFS). However, diligent infectious and viral monitoring and early, effective treatment of viral reactivation, in particular HHV6 and CMV is mandatory in SCD pts.
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN-BASED CONDITIONING REGIMEN IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE SERIES OF SINGLE CENTER EXPERIENCE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2774;
However, diligent infectious and viral monitoring and early, effective treatment of viral reactivation, in particular HHV6 and CMV is mandatory in SCD pts. In this retrospective study, we show that treosulfan-based conditioning regimen is a safe and effective treatment option in pediatric HSCT recipients, even in those with high-risk pre-HSCT clinical features or those with no HLA-identical family donor.
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN-BASED CONDITIONING AND SIROLIMUS-PTCY GVHD PROPHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AGGRESSIVE B-CELL NHL (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2773;
Chronic GvHD was not negligible but treatable in almost all cases. Selected pts with DLBCL, PMBCL, and MCL may still benefit from the inclusion of alloSCT in their treatment algorithm
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN-BASED CONDITIONING AND SIROLIMUS-PTCY GVHD PROPHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AGGRESSIVE B-CELL NHL (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2772;
Chronic GvHD was not negligible but treatable in almost all cases. Selected pts with DLBCL, PMBCL, and MCL may still benefit from the inclusion of alloSCT in their treatment algorithm
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN VERSUS BUSULFAN-BASED CONDITIONING REGIMENS FOR FIRST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN CHILDREN WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: A RETROSPECTIVE PDWP/EBMT STUDY (Hall 3 North) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2771;
Data collection on veno-occlusive disease post-HCT is ongoing. The prospective randomized trial comparing BuCyMel vs TreoFluThio in pediatric AML patients will provide more definitive answers on the differences in outcomes between these two regimens
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN- VERSUS BUSULFAN-BASED CONDITIONING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME: A SINGLE-CENTRE RETROSPECTIVE PROPENSITY SCORE-MATCHED COHORT STUDY (Hall 3 North) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2770;
This study is the first to utilize propensity score matching in assessing the role of treosulfan in stem cell transplantation of MAC ineligible patients with MDS and contributes to the increasing body of evidence supporting the antileukemic properties of the drug while underscoring its safety, even at the dose of 42 g/m2. Randomized controlled trials comparing treosulfan given at 30 g/m2 and 42 g/m2 are warranted.
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN PLUS FLUDARABINE (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2769;
This reduced intensity conditioning (T10F) would seem to limit relapse and GvHD without increasing TRM. Multicentric and larger studies with similar platforms are needed to confirm our results.
- Ovastat (treosulfan) / Medac, Medexus
TREOSULFAN PLUS FLUDARABINE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2768;
This reduced intensity conditioning (T10F) would seem to limit relapse and GvHD without increasing TRM. Multicentric and larger studies with similar platforms are needed to confirm our results.
- Ovastat (treosulfan) / Medac, Medexus, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
TOXIC EFFECTS OF IMMUNOTHERAPY FOR CHILDREN WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2749;
Multicentric and larger studies with similar platforms are needed to confirm our results. Conditioning regimens: ALL
- Ovastat (treosulfan) / Medac, Medexus
THE RESULTS OF ALLOGENEIC HSCT AFTER TREOSULFAN (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2707;
In the conditioning regimen treosulfan was combined with different cytostatics, mostly fludarabine (n=72; 84,7%) and cyclophosphamide (n=11; 12,9%)...There was no significant difference in outcome after treosulfan-fludarabine-thiotepa regimen versus other treosulfan-based regimens... Treosulfan-based regimen seems to be safe and effective in pediatric AML patients and may be used as an alternative to busulfan-based protocols, especially in patients with pre-HSCT high risk factors of severe regimen-related toxicities.
- Ovastat (treosulfan) / Medac, Medexus
THE RESULTS OF ALLOGENEIC HSCT AFTER TREOSULFAN (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2706;
In the conditioning regimen treosulfan was combined with different cytostatics, mostly fludarabine (n=72; 84,7%) and cyclophosphamide (n=11; 12,9%)...There was no significant difference in outcome after treosulfan-fludarabine-thiotepa regimen versus other treosulfan-based regimens... Treosulfan-based regimen seems to be safe and effective in pediatric AML patients and may be used as an alternative to busulfan-based protocols, especially in patients with pre-HSCT high risk factors of severe regimen-related toxicities.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH CHEMOREFRACTORY ACUTE MYELOID LEUKEMIA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2693;
Our data suggest that allogenic HSCT provides a reasonable chance of cure in a cohort of children with chemorefractory AML and creates a solid basis for further improvement. Good early recovery of NK cells and lower BM burden at the moment of HSCT are associated with significantly improved survival and decreased relapse incidence.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH CHEMOREFRACTORY ACUTE MYELOID LEUKEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2692;
Our data suggest that allogenic HSCT provides a reasonable chance of cure in a cohort of children with chemorefractory AML and creates a solid basis for further improvement. Good early recovery of NK cells and lower BM burden at the moment of HSCT are associated with significantly improved survival and decreased relapse incidence.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
TCR??+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2624;
We confirm that the depletion of TCR-alpha/beta and CD19 lymphocytes from the graft ensures high engraftment rate, low burden of GvHD and acceptable TRM in pediatric high-risk AML patients. AD status prior HSCT and absence of serotherapy in CR group are associated with high relapse rate and low survival.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
TCR??+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2623;
We confirm that the depletion of TCR-alpha/beta and CD19 lymphocytes from the graft ensures high engraftment rate, low burden of GvHD and acceptable TRM in pediatric high-risk AML patients. AD status prior HSCT and absence of serotherapy in CR group are associated with high relapse rate and low survival.
- Ovastat (treosulfan) / Medac, Medexus
TCR-?? DEPLETED HAPLOIDENTICAL TRANSPLANT WITH CD 45 RA- DEPLETED MEMORY T CELL ADD-BACK IN PAEDIATRIC NON-MALIGNANT DISEASES IN A SINGLE PAEDIATRIC CENTER: 10-YEAR RESULTS (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2622;
AD status prior HSCT and absence of serotherapy in CR group are associated with high relapse rate and low survival. Data was censored at patient
- Ovastat (treosulfan) / Medac, Medexus
TCR-?? DEPLETED HAPLOIDENTICAL TRANSPLANT WITH CD 45 RA- DEPLETED MEMORY T CELL ADD-BACK IN PAEDIATRIC NON-MALIGNANT DISEASES IN A SINGLE PAEDIATRIC CENTER: 10-YEAR RESULTS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2621;
Data was censored at patient Data was censored at patient
- thiotepa / Generic mfg.
T CELL REPLETE MYELOABLATIVE HAPLOIDENTICAL STEM CELL TRANSPLANT USING THIOTEPA BASED CONDITIONING- SINGLE CENTRE STUDY FROM INDIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2603;
Pre transplantation disease status (beyond CR1) was one of the main factors associated with the poor OS and DFS. Thiotepa based conditioning regimen is an appealing platform in the haplo-HSCT setting with PT-Cy in terms of engraftment rate, toxicity, and disease control.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
SUCCESSFUL THIRD ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING TWO GRAFT REJECTIONS IN A PATIENT WITH CHRONIC GRANULOMATOUS DISEASE AND HEPATIC/PARAPHRENIC ABSCESSES (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2588;
In CGD patients infectious complications may trigger graft rejections due to strong immune stimulation. In cases of graft rejections even second and third allogeneic stem cell transplantations may be performed successfully.
- Ovastat (treosulfan) / Medac, Medexus
SINGLE CENTER OBSERVATION ON CLINICAL PRESENTATION, TRANSPLANTATION AND OUTCOME OF SEVEN PATIENTS WITH ZAP-70 DEFICIENCY (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2546;
One patient received his graft from a MUD after a RIC regimen containing Melphalan and Fludarabin. The remaining 3 patients were treated with myeloablative regimens containing Busulfan or Treosulfan in combination with Fludarabin and Thiotepa.Acute GvHD ?II
- Ovastat (treosulfan) / Medac, Medexus
SINGLE CENTER OBSERVATION ON CLINICAL PRESENTATION, TRANSPLANTATION AND OUTCOME OF SEVEN PATIENTS WITH ZAP-70 DEFICIENCY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2545;
One patient received his graft from a MUD after a RIC regimen containing Melphalan and Fludarabin. The remaining 3 patients were treated with myeloablative regimens containing Busulfan or Treosulfan in combination with Fludarabin and Thiotepa.Acute GvHD ?II
- Ovastat (treosulfan) / Medac, Medexus, Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
SICKLE CELL DISEASE WITH SEVERE ACUTE CHEST SYNDROME AND HEPATOPATHY: CAN ALLOGENEIC SCT BE PERFORMED IN SUCH DESPERATE CLINICAL SITUATIONS? - A CASE REPORT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2538;
The presented case proves that patients with severe and complicated courses of SCD can be cured by HSCT. Careful and interdisciplinary considerations are important to manage such devastating and desperate cases.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
SEQUENTIAL KIDNEY-STEM CELL TRANSPLANTATION IN PATIENT WITH SCHIMKE IMMUNO-OSSEOUS DYSPLASIA: CASE REPORT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2524;
Moreover, the good outcome of HSCT is the reason for the development of immune tolerance to kidney graft and an argument for the full withdrawal of IST. However, the optimal approach remains unclear considering limited data and potential transplant-related challenges in SIOD patients.
- Ovastat (treosulfan) / Medac, Medexus, Amsidine (amsacrine) / Kyowa Kirin
SEQUENTIAL CONDITIONING DOES NOT IMPROVE OUTCOMES OF ALLOGENEIC STEMCELL TRANSPLANTATION IN CMML PATIENTS (GALA) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2520;
This retrospective study from the Department of Stem Cell Transplantation at the University Medical Center Hamburg, Germany, compared allo-SCT outcomes in CMML patients across three conditioning regimes: Thiotepa-Busulfan (TB), Sequential FLAMSA-Busulfan Fludarabine (FLAMSA-FB), and Treosulfan-Fludarabine (Treo-Flu)...FLAMSA-FB regimen consists of fludarabine (30 mg/m2 ; total dose 120 mg/m2 ), amsacrine (100 mg/m2 ; total dose 400 mg/m 2 ), and cytarabine (1 g/m2 ; total dose 4 g/m 2 ) therapy from days -11 to minus -8, followed by a three-day interval without therapy and Busulfan from day -4 to -2 with a total dose of 6.4mg/Kg and Fludarabine on day -4 and -3 (30 mg/m2, total dose 60mg/m 2 ).Treo-Flu regimen consisted of Treosulfan (12 g/m2 , total dose 36 mg/m2 ) on days-6 to -4 and fludarabine (30 mg/m2 ; total dose 150 mg/m2 ) on days -6 to -2... Our study suggests that sequential conditioning with FLAMSA-FB does not improve Transplant outcomes in patients undergoing allo-SCT for CMML.
- Ovastat (treosulfan) / Medac, Medexus
REAL-WORLD, SINGLE-CENTRE OUTCOME DATA OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION UTILISING TREOSULFAN-BASED CONDITIONING REGIMENS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2406;
ATG effectively mitigates severity of chronic GVHD relative to PTCy but increases incidence of infection. PTCy was associated with slower platelet engraftment in this cohort.
- Venclexta (venetoclax) / Roche, AbbVie
REAL-WORLD EFFECTIVENES OF VENETOCLAX COMBINED WITH IPOMETILATING-AGENTS AS A BRIDGE TO ALLOGENEIC TRANSPLANTATION IN ACUTE MIELOID LEUKEMIA: RETROSPECTIVE AND MULTICENTRIC STUDY OF APULIAN HEMATOLOGICAL NETWORK (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2392;
Our results albeit obtained in a small series of patients shown how the VEN-HMA combination should be regarded as a good bridge to allo-HSCT both in ND-AML and R/R AML. Multicentric and larger studies with similar platforms are needed to confirm our results.
- Venclexta (venetoclax) / Roche, AbbVie
REAL-WORLD EFFECTIVENES OF VENETOCLAX COMBINED WITH IPOMETILATING-AGENTS AS A BRIDGE TO ALLOGENEIC TRANSPLANTATION IN ACUTE MIELOID LEUKEMIA: RETROSPECTIVE AND MULTICENTRIC STUDY OF APULIAN HEMATOLOGICAL NETWORK (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2391;
Our results albeit obtained in a small series of patients shown how the VEN-HMA combination should be regarded as a good bridge to allo-HSCT both in ND-AML and R/R AML. Multicentric and larger studies with similar platforms are needed to confirm our results.
- Ovastat (treosulfan) / Medac, Medexus, Orencia (abatacept) / BMS
PROMISING OUTCOMES IN HAPLOIDENTICAL TRANSPLANTATION USING ABATACEPT IN COMBINATION WITH POST TRANSPLANT CYCLOPHOSPHAMIDE IN TREOSULFAN BASED CONDITIONING REGIMEN (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2343;
Abatacept in combination with PTCy in hap-SCT using Treosulfan based conditioning appears to show promising outcome and acceptable toxicity. However, given the severity of chronic GVHD, larger prospective trials are required to evaluate this strategy.
- Ovastat (treosulfan) / Medac, Medexus, Orencia (abatacept) / BMS
PROMISING OUTCOMES IN HAPLOIDENTICAL TRANSPLANTATION USING ABATACEPT IN COMBINATION WITH POST TRANSPLANT CYCLOPHOSPHAMIDE IN TREOSULFAN BASED CONDITIONING REGIMEN (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2342;
Abatacept in combination with PTCy in hap-SCT using Treosulfan based conditioning appears to show promising outcome and acceptable toxicity. However, given the severity of chronic GVHD, larger prospective trials are required to evaluate this strategy.
- Rituxan (rituximab) / Roche
PRETREATMENT WITH RITUXIMAB IS SUSPECTED TO INCREASE RISK FOR OCCURRENCE OF VENO-OCCLUSIVE DISEASE IN PATIENTS WITH AGGRESSIVE LYMPHOMA AFTER ALLOGENEIC TRANSPLANT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2329;
We suspect rituximab as a risk factor for the induction of VOD/SOS in patients after HSCT. More studies are required to confirm our findings.
- Orencia (abatacept) / BMS, Entyvio (vedolizumab) / Takeda
POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT, AND VEDOLIZUMAB TO PREVENT GVHD AFTER HSCT FROM HAPLOIDENTICAL DONORS IN CHILDREN WITH ACUTE LEUKEMIA: RESULTS OF A PROSPECTIVE TRIAL (Hall 5) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2294;
P3
Our data suggest that adding vedolizumab and abatacept to the PTCy-based GVHD prophylaxis backbone is well tolerated and ensures high engraftment rate and low transplant-related mortality. This approach can be further developed to reduce exposure to calcineurin inhibitors and deploy additional anti-leukemia effectors after HSCT
- Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi
OUTCOMES OF SECOND CONDITIONED TRANSPLANT AFTER AN UNCONDITIONED STEM CELL INFUSION IN INFANTS AND CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID) (CARRON) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2193;
These results demonstrate that a second conditioned SCT can successfully be performed following an initial unconditioned infusion. Pre-emptive conditioned SCT should be considered in a suitable candidate before onset of immune dysfunction
- Ovastat (treosulfan) / Medac, Medexus
OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2182;
Our findings suggest that haploidentical donor transplantation using ptCy leads to similar results as MSD and MUD transplantation in patients with myelodysplastic syndromes. Haploidentical donor transplantation could have an OS superiority in High and Very high risk MDS patients according to IPSS.
- Ovastat (treosulfan) / Medac, Medexus
OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2181;
Our findings suggest that haploidentical donor transplantation using ptCy leads to similar results as MSD and MUD transplantation in patients with myelodysplastic syndromes. Haploidentical donor transplantation could have an OS superiority in High and Very high risk MDS patients according to IPSS.
- Ovastat (treosulfan) / Medac, Medexus
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH DIAMOND-BLACKFAN ANEMIA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2173;
The preparative regimen was busulfan/busilvex-based in 15 patients (51.7%) and treosulfan-based in 14 (50.3%). This data shows that nowadays both allo-HSCT from MSD and MUD is efficient and safe for DBA patients.
- Ovastat (treosulfan) / Medac, Medexus
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH DIAMOND-BLACKFAN ANEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2172;
The preparative regimen was busulfan/busilvex-based in 15 patients (51.7%) and treosulfan-based in 14 (50.3%). This data shows that nowadays both allo-HSCT from MSD and MUD is efficient and safe for DBA patients.
- Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi
OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH WISKOTT-ALDRICH SYNDROME (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2166;
GvHD prophylaxis was ciclosporin alone (n=4) or in combination with methotrexate (n=9) or MMF (n=13); none in three... Our Cohort
- Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi
OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH WISKOTT-ALDRICH SYNDROME (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2165;
GvHD prophylaxis was ciclosporin alone (n=4) or in combination with methotrexate (n=9) or MMF (n=13); none in three... Our Cohort
- Ovastat (treosulfan) / Medac, Medexus
OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION OF IN CHILDREN WITH A NPM1 MUTATION AND MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2138;
There was no significant difference in outcome of HSCT between the NPM mt and NPM1WT groups. The small number of NPM1 mutated pediatric patients in this cohort does not allow further conclusions on the role and indication of AML therapy or HSCT in young NPM1mt patients with a low blast count.
- Ovastat (treosulfan) / Medac, Medexus
LONG-TERM RESULTS OF RANDOMISED PHASE 2 TRIAL TO COMPARE TREOSULFAN WITH BUSULFAN BASED CONDITIONING IN CHILDREN WITH NON-MALIGNANT DISEASES (LOMOND) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1944;
P2
However, a higher risk of secondary graft failure when compared with busulfan-based conditioning was observed. Nevertheless, all but one of the 11 subjects with graft failure after treosulfan were successfully rescued and alive at last follow-up.
- Ovastat (treosulfan) / Medac, Medexus
IMPROVING OUTCOMES IN MDS/MPN: TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1825;
Treosulfan-based conditioning seems to be effective and well-tolerated in patients with MDS/MPN undergoing allo-HSCT, for both low risk of relapse and low TRM. Further studies on larger cohorts are necessary to confirm these findings and to clarify the role of pre-transplant induction treatment with HMAs or intensive chemotherapy in this disease setting.
- Ovastat (treosulfan) / Medac, Medexus
IMPROVING OUTCOMES IN MDS/MPN: TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1824;
Treosulfan-based conditioning seems to be effective and well-tolerated in patients with MDS/MPN undergoing allo-HSCT, for both low risk of relapse and low TRM. Further studies on larger cohorts are necessary to confirm these findings and to clarify the role of pre-transplant induction treatment with HMAs or intensive chemotherapy in this disease setting.
- cyclophosphamide / Generic mfg.
IMPLEMENTATION OF NON-TBI CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN RESOURCE-LIMITED SETTINGS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1810;
This study demonstrates the successful implementation of non-TBI-based conditioning regimens and emphasizes the role of PTCy in achieving favorable outcomes in a resource-limited setting. PTCy emerges as a crucial strategy in reducing GVHD risks and facilitating HSCT despite limited technological resources, offering hope for patients facing similar constraints worldwide.
- Ovastat (treosulfan) / Medac, Medexus
IMPACT OF PRETRANSPLANT MRD IN PATIENTS ALLOGRAFTED FOR AML AFTER TREOSULFAN-BASED CONDITIONING (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1787;
Our analysis shows that Flu/Treo-based conditioning cannot eliminate the negative impact of pretransplant MRD positivity on RFS. However, MRD positivity did not have an impact on OS in our analysis, which may be explained in part by graft-derived alloreactivity implied by cGvHD.
- Ovastat (treosulfan) / Medac, Medexus
IMPACT OF PRETRANSPLANT MRD IN PATIENTS ALLOGRAFTED FOR AML AFTER TREOSULFAN-BASED CONDITIONING (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1786;
Our analysis shows that Flu/Treo-based conditioning cannot eliminate the negative impact of pretransplant MRD positivity on RFS. However, MRD positivity did not have an impact on OS in our analysis, which may be explained in part by graft-derived alloreactivity implied by cGvHD.
- Ovastat (treosulfan) / Medac, Medexus
IMPACT OF MINIMAL RESIDUAL DISEASE AT HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WITHIN THE FORUM TRIAL (LOMOND) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1782;
P2/3
Out of the 1066 FORUM patients, 728 (36% female), transplanted (74% bone marrow graft) from a MSD (30%) or a MD (70%), after conditioning with TBI (67%) or chemotherapy only (busulfan 21% or treosulfan 12%), for ALL (59% B-lineage) in CR1 (50%), CR2 (43%) or >CR3 (7%), had MRD levels at HSCT available (79% by PCR and 21% by FCM).MRD upon HSCT. MRD at HSCT was highly predictive of EFS and relapse and the occurrence of mild GVHD was protective for EFS
- cyclosporine / Generic mfg.
IMPACT OF EARLY CYCLOSPORINE INITIATION ON CYTOKINE RELEASE SYNDROME AND TRANSPLANT OUTCOMES IN PEDIATRIC T CELL REPLETE PERIPHERAL BLOOD HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1768;
Peripheral blood graft is a valid option in haplo-HSCT in children with malignancy. Larger prospective studies would help in validating our outcomes.
- cyclosporine / Generic mfg.
IMPACT OF EARLY CYCLOSPORINE INITIATION ON CYTOKINE RELEASE SYNDROME AND TRANSPLANT OUTCOMES IN PEDIATRIC T CELL REPLETE PERIPHERAL BLOOD HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1767;
Peripheral blood graft is a valid option in haplo-HSCT in children with malignancy. Larger prospective studies would help in validating our outcomes.